No. S 9
Infectious Diseases Act 1976
Infectious Diseases
(COVID-19 Access Restrictions and Clearance)
(Amendment) Regulations 2022
In exercise of the powers conferred by section 73(1) of the Infectious Diseases Act 1976, the Minister for Health makes the following Regulations:
Citation and commencement
1.  These Regulations are the Infectious Diseases (COVID-19 Access Restrictions and Clearance) (Amendment) Regulations 2022 and come into operation on 6 January 2022.
Amendment of regulation 2
2.  Regulation 2(1) of the Infectious Diseases (COVID‑19 Access Restrictions and Clearance) Regulations 2021 (G.N. No. S 273/2021) (called in these Regulations the principal Regulations) is amended —
(a)by inserting, immediately after the definition of “entrant”, the following definition:
“ “medical treatment” includes a medical consultation, and a diagnostic procedure connected with any medical treatment;”;
(b)by inserting, immediately after the words “outside Singapore” in paragraph (a)(ii) of the definition of “recovered individual”, the words “or an antigen rapid test in or outside Singapore on or after 6 January 2022”;
(c)by deleting the words “in Singapore” where they last appear in paragraph (a)(iii) of the definition of “recovered individual” and substituting the words “or an antigen rapid test”;
(d)by inserting, immediately after sub‑paragraph (iii) of paragraph (a) of the definition of “recovered individual”, the following sub‑paragraph:
(iv)an antigen rapid test in Singapore on or after 6 January 2022 that is performed by or under the direction of the individual’s treating doctor in the course of providing medical treatment to the individual because the individual has acute respiratory symptoms;”; and
(e)by inserting, immediately after the definition of “suspended status interval”, the following definition:
“ “treating doctor”, for an individual, means a legally qualified medical practitioner who, in the course of providing medical treatment of the individual as a patient thereof, assesses the individual’s condition, whether remotely or in person;”.
Amendment of regulation 6
3.  Regulation 6 of the principal Regulations is amended —
(a)by deleting sub-paragraph (i) of paragraph (2)(a) and substituting the following sub‑paragraph:
(i)starting the date the recovered individual first tested positive for SARS‑CoV‑2 upon undergoing any of the following that led to the diagnosis of the individual having that infection:
(A)a polymerase chain reaction test;
(B)an antigen rapid test which had been followed by a serology test in Singapore that is not attributable to the administration of any vaccine against a COVID‑19 infection;
(C)an antigen rapid test on or after 6 January 2022 that is performed by or under the direction of the individual’s treating doctor in the course of providing medical treatment to the individual because the individual has acute respiratory symptoms; and”;
(b)by deleting sub-paragraph (i) of paragraph (2)(b) and substituting the following sub‑paragraph:
(i)starting the date the recovered individual first tested positive for SARS‑CoV‑2 upon undergoing any of the following that led to the diagnosis of the individual having that infection:
(A)a polymerase chain reaction test;
(B)an antigen rapid test followed by a serology test in Singapore that is not attributable to the administration of any vaccine against a COVID‑19 infection;
(C)an antigen rapid test on or after 6 January 2022 that is performed by or under the direction of the individual’s treating doctor in the course of providing medical treatment to the individual because the individual has acute respiratory symptoms; and”;
(c)by deleting sub-paragraph (c) of paragraph (5) and substituting the following sub‑paragraph:
(c)starting the date the recovered individual first tested positive for SARS‑CoV‑2 upon undergoing any of the following that led to the diagnosis of the individual having the last infection he or she recovered from:
(i)a polymerase chain reaction test;
(ii)an antigen rapid test followed by a serology test in Singapore that is not attributable to the administration of any vaccine against a COVID‑19 infection;
(iii)an antigen rapid test on or after 6 January 2022 that is performed by or under the direction of the individual’s treating doctor in the course of providing medical treatment to the individual because the individual has acute respiratory symptoms; and”;
(d)by deleting the words “(whether before, on or after 1 January 2022)” in paragraph (5A)(a), (b) and (c);
(e)by inserting, immediately after sub‑paragraph (ii) of paragraph (5A)(b), the following sub‑paragraphs:
(iii)an antigen rapid test followed by a serology test in Singapore that is not attributable to the administration of any vaccine against a COVID‑19 infection;
(iv)an antigen rapid test (on or after 6 January 2022) in Singapore that is performed by or under the direction of the individual’s treating doctor in the course of providing medical treatment to the individual because the individual has acute respiratory symptoms;”; and
(f)by deleting sub-paragraph (a) of paragraph (6).
Amendment of regulation 7A
4.  Regulation 7A(6) of the principal Regulations is amended by deleting sub‑paragraph (a).
Amendment of regulation 7B
5.  Regulation 7B(3) of the principal Regulations is amended by deleting sub‑paragraph (a).
Amendment of regulation 8A
6.  Regulation 8A of the principal Regulations is amended by deleting paragraph (4) and substituting the following paragraph:
(4)  In this regulation, a suspended status interval for an individual granted a certificate under regulation 6(2), (3), (4), (5) or (5A), 7A(2), (3) or (4) or 7B(2), means the period that he or she is subject to a movement control measure where that period falls after the grant of that certificate.”.
Amendment of First Schedule
7.—(1)  Item 1 of the First Schedule to the principal Regulations is amended by deleting the words “or (ii)” in the second column relating to paragraph (3) and substituting the words “, (ii) or (iv)”.
(2)  Item 2 of the First Schedule to the principal Regulations is amended by deleting the words “or (ii)” in the second column relating to paragraph (3) and substituting the words “, (ii) or (iv)”.
(3)  Item 3 of the First Schedule to the principal Regulations is amended by deleting the words “or (ii)” in the second column relating to paragraph (3) and substituting the words “, (ii) or (iv)”.
(4)  Item 4 of the First Schedule to the principal Regulations is amended by deleting the words “or (ii)” in the second column relating to paragraph (2) and substituting the words “, (ii) or (iv)”.
(5)  Item 5 of the First Schedule to the principal Regulations is amended by deleting the words “or (ii)” in the second column relating to paragraphs (3) and (10) and substituting in each case the words “, (ii) or (iv)”.
(6)  Item 6 of the First Schedule to the principal Regulations is amended by deleting the words “or (ii)” in the second column relating to paragraphs (3) and (10) and substituting in each case the words “, (ii) or (iv)”.
(7)  Item 7 of the First Schedule to the principal Regulations is amended by deleting the words “or (ii)” in the second column relating to paragraph (3) and substituting the words “, (ii) or (iv)”.
(8)  Item 8 of the First Schedule to the principal Regulations is amended by deleting the words “or (ii)” in the second column relating to paragraph (3) and substituting the words “, (ii) or (iv)”.
[G.N. Nos. S 310/2021; S 324/2021; S 367/2021; S 396/2021; S 513/2021; S 542/2021; S 590/2021; S 620/2021; S 682/2021; S 768/2021; S 774/2021; S 863/2021; S 908/2021; S 991/2021]
Made on 5 January 2022.
NG HOW YUE
Permanent Secretary
(Health Development),
Ministry of Health,
Singapore.
[AG/LEGIS/SL/137/2020/13 Vol. 4]